Compare KRYS & IT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KRYS | IT |
|---|---|---|
| Founded | 2015 | 1979 |
| Country | United States | United States |
| Employees | 295 | 40 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Other Consumer Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.1B | 9.8B |
| IPO Year | 2017 | 2010 |
| Metric | KRYS | IT |
|---|---|---|
| Price | $344.64 | $151.00 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 11 | 9 |
| Target Price | ★ $297.60 | $189.25 |
| AVG Volume (30 Days) | 548.4K | ★ 1.2M |
| Earning Date | 05-04-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 128.00 | N/A |
| EPS | 1.83 | ★ 3.18 |
| Revenue | $389,130,000.00 | ★ $2,021,441,000.00 |
| Revenue This Year | $38.74 | $3.52 |
| Revenue Next Year | $32.53 | $5.08 |
| P/E Ratio | $199.26 | ★ $47.80 |
| Revenue Growth | ★ 33.94 | 13.30 |
| 52 Week Low | $130.50 | $124.25 |
| 52 Week High | $382.54 | $337.29 |
| Indicator | KRYS | IT |
|---|---|---|
| Relative Strength Index (RSI) | 48.69 | 55.77 |
| Support Level | $246.17 | $142.37 |
| Resistance Level | $382.33 | $162.80 |
| Average True Range (ATR) | 18.24 | 6.97 |
| MACD | -0.46 | 2.60 |
| Stochastic Oscillator | 53.10 | 58.28 |
Krystal Biotech Inc is an integrated, commercial-stage biotechnology company focused on the discovery, development, manufacturing, and commercialization of genetic medicines to treat diseases with high unmet medical needs. The company uses its patented HSV-1-based gene therapy platform to create vectors that deliver therapeutic transgenes to target cells. It possesses exclusive rights to develop, manufacture, and commercialize VYJUVEK internationally. The company operates as one operating segment focused on pharmaceutical products and manufactures, markets, and sells VYJUVEK in the United States and markets and sells VYJUVEK in the European Union, and Japan.
Gartner Inc delivers actionable, objective business and technology insights that drive smarter decisions and stronger performance on an organization's mission-critical priorities. It delivers its products and services globally through three reportable segments - Business and Technology Insights, Conferences and Consulting. Insights equips executives and their teams from every Majority function, geography, industry and sector with actionable, objective insights, guidance and tools. Conferences provides executives and teams across an organization the opportunity to learn, share and network. and Consulting serves senior executives technology-driven strategic initiatives leveraging the power of Gartner's actionable, objective insight. The Majority revenue is derived from the Insights segment.